A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
Condition: HIV-1 Interventions: Drug: D/C/F/TAF FDC; Drug: TAF/FTC FDC; Drug: INI Based Regimen Sponsor: Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2020 Category: Research Source Type: clinical trials
